Lens
 
International AIDS Society

IAS TB/HIV Research Prize



To contribute to generating interest and stimulating research on basic, clinical and operational research in TB/HIV prevention, care and treatment, the IAS TB/HIV Research Prize was first awarded in 2009 at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Cape Town.

The US$2,000 IAS TB/HIV Research Prize in an incentive for young and established researchers to investigate pertinent research questions that affect TB/HIV co-infection and operational effectiveness of implementing core TB/HIV collaborative services.

To be eligible for the prize, abstracts submitted to AIDS 2014 must meet the following criteria:
  • The abstract must have been accepted as an oral presentation, poster discussion or poster exhibition by the Scientific Programme Committee
  • Research must be related to HIV and TB

ABSTRACT SUBMITTERS DO NOT NEED TO APPLY FOR THE PRIZE.

All abstract submitters who meet the criteria are automatically considered.


Previous Prize Winners


2013 IAS TB/HIV Research Prize

James Houston, United States, for the abstract, Tuberculosis burden is a barrier to starting isoniazid preventive therapy in HIV-infected children enrolled in care.


2012 IAS TB/HIV Research Prize

Jonathan Golub, USA, for the abstract, “The TB/HIV in Rio de Janeiro (THRio) study: a step-wedged cluster randomized trial measuring the impact of tuberculosis (TB) screening and isoniazid preventive therapy (IPT) on incidence of TB and death”.


2011 IAS TB/HIV Research Prize

Sabine Margot Hermans, The Netherlands, for her abstract, “Integration of HIV and TB services results in earlier and more prioritised ART initiation in Uganda”.


2010 IAS TB/HIV Research Prize

Katherine Todrys, UK, for her abstract, “HIV and TB management in six Zambian prisons demonstrate improved but ongoing prevention, testing and treatment gaps”.


2009 IAS TB/HIV Research Prize

Clare van Halsema, UK, for her abstract, “Good tuberculosis treatment outcomes and no evidence of increased drug resistance in individuals previously exposed to isoniazid preventive therapy in a population with high HIV prevalence”.

 



Sponsors